Related Experiment Video
Updated: May 12, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Properly diagnosing pulmonary arterial hypertension
1Pulmonary and Critical Care Division, New England Medical Center, Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA. ipreston@tuftsmedicalcenter.org
Abstract:
Pulmonary hypertension (PH) is found in many clinical conditions and is associated with increased morbidity and mortality. Pulmonary arterial hypertension (PAH) is a clinical condition characterized by precapillary PH without causes such as lung disease, chronic thromboembolic PH, or other rare conditions. Evaluating a patient with suspected PH requires a series of investigations intended to confirm the diagnosis, determine the clinical PH group (and, in the case of PAH group 1, the specific etiology), and evaluate the functional and hemodynamic impairment. The workup should identify the risk factors for PH (e.g., left heart disease, lung diseases associated with alveolar hypoxia, and chronic thromboembolism) versus the conditions associated with PAH group 1 (e.g., scleroderma, human immunodeficiency virus, anorexigen use, liver disease). A detailed algorithm is presented to help physicians determine the appropriate PH category. Because the presence of one condition associated with PH does not exclude another etiologies, clinicians are strongly encouraged to follow the entire algorithm. Discussions and case studies are presented describing the differentiation of PAH group 1 from PH group 2 and PAH group 1 from PH group 3; diagnosing PH group 4; determining the long-term calcium channel blocker response in those with idiopathic PAH; and determining the severity of PH.
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Cardiac Catheterization II: Right Heart Catheterization
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

